A Strategy of High-Dose Lenalidomide in Combination with Epigenetic Therapies for Relapsed or Refractory Acute Myeloid Leukaemia (AML)- Phase II
Latest Information Update: 18 Jun 2019
At a glance
- Drugs Lenalidomide (Primary) ; Azacitidine; Romidepsin
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 18 Jun 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 03 Jun 2017 Planned initiation date changed from 1 Jan 2013 to 1 Jun 2018.
- 23 Jun 2016 New trial record